Journal article
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Abstract
BACKGROUND: Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The randomized, open-label, phase III study FORWARD I compared MIRV and investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC).
PATIENTS AND METHODS: Eligible patients with 1-3 prior lines …
Authors
Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL
Journal
Annals of Oncology, Vol. 32, No. 6, pp. 757–765
Publisher
Elsevier
Publication Date
6 2021
DOI
10.1016/j.annonc.2021.02.017
ISSN
0923-7534